Our team is committed to developing new medicines to treat life-altering central nervous system (CNS) disorders. We are focused on advancing novel therapies through our understanding of the disease biology and translational findings. Our trials serve carefully selected patient populations who have limited treatment options.
A Phase 3 trial evaluating an oral therapeutic candidate in the treatment of postpartum depression (PPD).
This research study is evaluating the efficacy and safety of an investigational oral medication in women with PPD. An investigational medication is a study drug that will be tested during a study to see if it is safe and effective for a specific condition and/or group of people.
For more information about this trial and participating locations, visit the Robin Study website.
We are committed to respecting the primary role of healthcare providers in the treatment of CNS disorders. Therefore, we cannot respond to medical questions about your personal health situation, nor can we accept private medical information. Please contact your healthcare provider with any questions pertaining to your or a family member’s medical condition.